Sean Brynjelsen
CIK 1669976 · President & CEO · last filed 2026-08-20
Sean Brynjelsen is a President & CEO who has filed 29 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing, for ETON, was dated Aug 20, 2026. Across all open-market trades the lifetime net is −$13.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $54.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ETON price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
21925 W FIELD PKWY #235
DEER PARK, IL 60010
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ETON | President & CEO | 1,077,156 | $50.17 | $54.04M | -$13.24M | 21 | 2026-08-20 |
| Sagent Pharmaceuticals, Inc. (SGNT) Delisted | EVP, Business Development | 9,844 | — | — | $0 | 1 | 2016-04-06 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-20 | ETON | Notice (144/A) | −100,000 | -$6.34M | EDGAR |
| 2026-08-20 | ETON | Sell (S) | −100,000 | -$6.09M | EDGAR |
| 2026-08-19 | ETON | Notice (144) | −100,000 | -$6.34M | EDGAR |
| 2026-08-04 | ETON | Grant (A) | — | $0 | EDGAR |
| 2026-07-14 | ETON | Exer (M) | +227,500 | $274.0K | EDGAR |
| 2026-05-29 | ETON | Sell (S) | −120,000 | -$3.83M | EDGAR |
| 2026-05-28 | ETON | Notice (144) | −120,000 | -$3.89M | EDGAR |
| 2026-01-14 | ETON | Notice (144) | −5,015 | -$77.2K | EDGAR |
| 2026-01-14 | ETON | Mixed | −5,015 | -$77.2K | EDGAR |
| 2025-12-12 | ETON | Notice (144) | −8,035 | -$135.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.